CoChat

Angiotensin-Converting Enzyme Inhibitors and Kidney Protection: The AIPRI Trial

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

A protective effect of angiotensin-converting enzyme (ACE) inhibitors has been shown in patients with diabetic nephropathy but has not been clearly established in nondiabetic renal disease. A multicenter European study was designed to determine whether the ACE inhibitor benazepril was safe and effective in protecting residual renal function in patients with various renal diseases and mild to moderate renal failure. The trial involved 583 patients from 49 centers in Italy, France, and Germany. The patients were randomized to receive benazepril or placebo plus other antihypertensive agents, the target being a diastolic blood pressure of less than 90 mm Hg. Thirty-one patients in the benazepril group and 57 patients in the placebo group reached the end point [the time elapsed from entry to (a) doubling of serum creatinine (SCr) concentrations and (b) start of renal replacement therapy; p < 0.001 at 3 years]. The associated reduction in the relative risk of reaching the end point was 53% in benazepril-treated patients, with actuarial renal survival probability significantly better at 3 years. The best survival of renal function was observed in patients with chronic glomerular diseases and proteinuria greater than 1.0 g/24 h. Benazepril is effective in slowing the rate of progression and improving the survival of renal function in patients with renal diseases of various origins. This protective effect is associated with a clinically relevant decrease in both blood pressure and proteinuria.

Overview

Integrity signals

Registry

Crossref · 10.1097/00005344-199900001-00004

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 11 references

Research works printed but not linked: 4

  1. Apperloo, 1994, Kidney Int, 45, S174
  2. Becker, 1994, Kidney Int, 45, S167
  3. Peterson, 1993, J Am Soc Nephrol, 4, 254A
  4. Gansevoort, 1994, J Am Soc Nephrol, 5, 329A

Cited by

See all 84

Metadata

Authors
Maschio, G., Alberti, D., Locatelli, F., Mann, J. F. E., Motolese, M., Ponticelli, C., Ritz, E., Janin, G., & Zucchelli, P.
Affiliations
  • IRCCS Humanitas Research Hospital (IT)
  • Heidelberg University (DE)
  • University of Bologna (IT)
Corresponding author
Maschio, G.
Venue
Journal of Cardiovascular Pharmacology
Published
1999
Volume
33
Pages
S16-S20
ISSN
0160-2446 (ISSN-L)
OpenAlex
W2035875362
Cited by
77
References
11
Citations by year
2026: 1 · 2025: 1 · 2024: 3 · 2023: 5 · 2022: 3 · 2021: 4 · 2020: 1 · 2019: 2 · 2018: 3 · 2017: 2 · 2015: 3 · 2014: 1 · 2013: 4 · 2012: 2
FWCI
2.51
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Cardiovascular Pharmacology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
  • Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
Keywords
ACE inhibitors, benazepril, renal protection, chronic kidney disease, renal function decline, proteinuria, glomerular disease, antihypertensive therapy, blood pressure reduction, renal survival, diabetic nephropathy
MeSH terms
Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Benzazepines, Blood Pressure, Creatinine, Female, Humans, Kidney Diseases, Male, Placebos, Prospective Studies, Proteinuria, Renal Insufficiency

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Angiotensin-Converting Enzyme Inhibitors and Kidney Protection: The AIPRI Trial. https://app.cochat.ai/papers/10.1097/00005344-199900001-00004
The paper
Maschio, G., Alberti, D., Locatelli, F., Mann, J. F. E., Motolese, M., Ponticelli, C., Ritz, E., Janin, G., & Zucchelli, P. (1999). Angiotensin-Converting Enzyme Inhibitors and Kidney Protection: The AIPRI Trial. Journal of Cardiovascular Pharmacology. https://doi.org/10.1097/00005344-199900001-00004

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.